{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:54:56Z","timestamp":1790999696573,"version":"4.1.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8208-26","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:51Z","timestamp":1790633511000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effects of Pemafibrate Extended-Release in Patients with Hypertriglyceridemia: A 12-Month Retrospective Study"],"prefix":"10.2169","author":[{"given":"Saori","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syusaku","family":"Kanemori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiichiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Meitetsu Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab 103: 3019-3027, 2018.","DOI":"10.1210\/jc.2018-00470"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123: 2292-2333, 2011.","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191: 235-240, 2007.","DOI":"10.1016\/j.atherosclerosis.2006.08.021"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77: 1797-1835, 2023.","DOI":"10.1097\/HEP.0000000000000323"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73-84, 2016.","DOI":"10.1002\/hep.28431"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69: 1691-1705, 2020.","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16: 124, 2017.","DOI":"10.1186\/s12933-017-0602-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12: 173-184, 2018.","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kamata S, Honda A, Ishii I. Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease. Biomolecules 13: 1264, 2023.","DOI":"10.3390\/biom13081264"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 6: 270-274, 2020.","DOI":"10.5114\/ceh.2020.99528"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Suzuki T, Sato T, Tanaka M, et al. Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 16: 1496671, 2025.","DOI":"10.3389\/fendo.2025.1496671"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Arai H, Yamashita S, Araki E, et al. Efficacy and safety of pemafibrate extended-release tablet: a phase 3, multicenter, randomized, double-blind, active-controlled, parallel-group comparison trial. J Atheroscler Thromb 31: 1517-1538, 2024.","DOI":"10.5551\/jat.64677"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamashita S, Araki E, Arai H, et al. Clinical pharmacology of pemafibrate extended-release formulation in patients with hypertriglyceridemia-a phase 2, multicenter, active-controlled, randomized, single-blind, crossover study. J Atheroscler Thromb 32: 367-384, 2025.","DOI":"10.5551\/jat.65001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296-1310, 2001.","DOI":"10.1016\/S0149-2918(01)80109-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012: 527-539, 2012.","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"16","unstructured":"16. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 387: 1923-1934, 2022."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yokote K, Yamashita S, Arai H, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol 20: 96, 2021.","DOI":"10.1186\/s12933-021-01291-w"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yamashita S, Rizzo M, Su TC, Masuda D. Novel selective PPAR\u03b1 modulator pemafibrate for dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis. Metabolites 13: 626, 2023.","DOI":"10.3390\/metabo13050626"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne) 10: 1073025, 2023.","DOI":"10.3389\/fmed.2023.1073025"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 29: 3-8, 2016.","DOI":"10.1016\/j.ejim.2015.11.026"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149: 389-397, 2015.","DOI":"10.1053\/j.gastro.2015.04.043"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8208-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:20Z","timestamp":1790998220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8208-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8208-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8208-26"}}